VIP vs SLU-PP-332
Side-by-side comparison of key properties, dosing, and research.
Immune SupportSleep Optimization
VIPRecovery & RepairFat Loss & Metabolic
SLU-PP-332- Summary
- VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Half-Life
- ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
- Not established in humans; rodent pharmacokinetics suggest hours
- Admin Route
- Intranasal, SubQ, IV
- Oral (research), Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 50 mcg (4 sprays of 12.5 mcg each)
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- 4x daily
- Once daily in rodent studies
- Key Benefits
- Potent anti-inflammatory for CIRS and mold illness
- Improves pulmonary hypertension symptoms
- Regulates gut motility and IBS symptoms
- Modulates circadian rhythm and sleep quality
- Reduces mast cell activation (MCAS)
- Improves cognitive function in neuroinflammatory conditions
- Vasodilatory — reduces vascular resistance
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Side Effects
- Facial flushing (transient, intranasal)
- Mild nausea
- Headache at initiation
- Hypotension at high doses
- +1 more
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Stacks With
- —
- —